ArticleFrontiers in genetics2026
Clinical application value of preconception and prenatal carrier screening in Yinchuan.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the clinical application value of Expanded Carrier Screening (ECS) in preconception and prenatal populations in Yinchuan. Methods: A total of 1,319 participants underwent ECS, including 1,063 females receiving preconception or prenatal screening and 256 males. Among them, 157 couples completed full paired ECS testing, while the remaining participants only received single-individual testing. Results: 332 individuals were identified as carriers of single-gene diseases, with a total carrier rate of 25.17%. The GJB2 gene had the highest mutation frequency, with a carrier rate of 8.87%, followed by PAH, SLC26A4, and ATP7B. A total of 5 high-risk couples (5/157, 3.18%) were identified. After genetic counseling, 2 couples underwent prenatal amniotic fluid diagnosis: one case was diagnosed with Duchenne/Becker muscular dystrophy and opted for induced abortion, while one couple was a carrier of the GJB2 gene, and the newborn passed the hearing screening test. A pregnant woman had a spontaneous abortion of unknown cause, and a carrier of the GJB2 gene, declined prenatal diagnosis and has not yet delivered. The last couple are carriers of GJB2 gene, and the woman is not yet pregnant, comprehensive genetic counseling has been provided regarding transmission risks and available reproductive options. Conclusion: ECS is a useful tool for identifying high-risk couples in preconception and prenatal settings and for informing genetic counseling and reproductive planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.